Elixion Biotech validates its quantum-informed R&D process, proving readiness to advance precision medicines

Zurich, 23 October 2025. Elixion Biotech emerges from stealth, announcing the in-silico validation of five targets via its unique, quantum physics-informed drug development process. Validation confirms the predictive power of its R&D approach and paves the way for the next phase of precision-medicine development. Completed in only eleven months and entirely self-funded, this breakthrough demonstrates Elixion’s commitment to bringing new discoveries to patients faster.

Elixion’s first validation programme targets breast cancer, one of the leading causes of cancer-related mortality worldwide. Within this area, HER2-negative and triple-negative breast cancers (TNBC) remain among the most challenging to treat and represent major unmet needs. The results confirm that Elixion’s quantum-informed approach can accurately recover known biomarkers such as HER2/ERBB2, ESR1, BRCA1, and BRCA2, and identify new, clinically relevant therapeutic targets and molecular pathways not detected through conventional methods.

“This is more than a technical milestone; it’s proof that our process works,” said Marco Piccinini, Co-Founder and CEO of Elixion Biotech. “We’ve shown that our quantum-informed approach can uncover meaningful targets with real potential to become tomorrow’s medicines. With this validation, we’re ready to move from stealth to scale and from prediction to preclinical development.”

Elixion’s R&D approach combines quantum physics, causal biology, multi-omics, and native AI, bringing an unprecedented level of accuracy and efficiency to early-stage drug discovery:

• Quantum physics-informed target identification increases the precision and speed of discovery by filtering biological relevance from vast multi-omics datasets while preserving key genetic relationships.
• Atomic-level modelling of molecular interactions improves drug design through earlier and more reliable predictions of efficacy, toxicity, and stability.
• Quantum-informed AI investigation and engineering enables the discovery of novel molecules that remain invisible to traditional approaches.

In business terms, this precision translates into faster, more efficient R&D, allowing Elixion to prioritise the most promising drug targets early, reduce costly failures, and accelerate progress toward therapies ready for clinical development. It’s a model designed to deliver scientific depth with commercial discipline.

With in silico validation complete, the company is now preparing for wet-lab validation and preclinical translation, moving its targets into compound design and functional studies. Having been entirely self-funded through its pre-seed stage, Elixion is now opening its seed round to accelerate the development of its precision-oncology pipeline.

About Elixion Biotech

Elixion Biotech is a Zurich-based biotechnology company developing novel therapeutics through a unique R&D approach that combines quantum physics, causal biology, multi-omics, and native AI. This precision-driven process allows Elixion to uncover the true mechanics of disease, reduce the guesswork that slows discovery, and design better drugs from the start. Focused on complex diseases with high unmet needs, the company’s mission is to bring life-changing discoveries to patients faster.